• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    福

    福山市民病院

    Fukuyama City Hospital
    EST. 1977
    545论文总数
    5,619引用总数

    论文量&引用量时间轴

    机构学者

    论文(545)

    年份
    起
    –
    止
    排序
    1Validation of the Institute Mutualiste Montsouris System for the Stratification of Laparoscopic Liver Resections: an International Multicenter Study.
    Alessandro Mazzotta,David Fuks,Olivier Soubrane,Hwee-Leong Tan, Nicholas L Syn,Safi Dokmak,Salvatore Gruttadauria,Federica Cipriani,Giuseppe Zimmitti, Mohammad Alzoubi,Atsushi Sugioka,Olivier Scatton,

    Background:The Institut Mutualiste Montsouris (IMM) 3-level complexity classification has been validated for laparoscopic liver resection (LLR) in several studies with small sample size. However, it has not been well-validated in large studies down to the individual procedure type. Hence, in order to address current limitations in the studies validating the IMM complexity classification, we performed an international multicenter study to validate the IMM complexity classification across its three complexity levels and the categorization of the 11 distinct procedure types. Methods:A retrospective cohort study of 22,252 patients undergoing LLR across 64 centers worldwide between 2005 and 2021 was performed. Baseline characteristics and perioperative outcomes were analyzed across the three difficulty levels and 11 procedure types of the IMM complexity classification. Results:A total of 14,765 patients were included in our final analysis. The main indications for LLR in our study was hepatocellular carcinoma or intrahepatic cholangiocarcinoma (n=7,781, 52.7%) followed by liver metastasectomy (n=3,911, 26.5%). In terms of underlying liver pathology, 5,127 (34.7%) cases had cirrhosis, and 1,214 (8.3%) had portal hypertension. Perioperative outcomes including operative time, open conversion rate, intraoperative blood loss, need for intraoperative blood transfusion, need for Pringle's application, length of stay, postoperative morbidity, major postoperative morbidity and 90-day mortality all demonstrated a significant increasing trend with increasing IMM complexity grades (P<0.001). These trends remained significant following adjustment for baseline characteristics (P<0.001). Notably, when examining the 11 LLR procedure types, all procedures within each IMM complexity grade were individually higher than all procedures in the preceding complexity grade for operative time, blood loss, length of stay, postoperative morbidity and major postoperative morbidity. Conclusions:The three IMM complexity grades were well associated with LLR complexity as determined by key surrogate perioperative measures. Our findings also supported the categorization of the 11 distinct LLR procedures into the three complexity levels.

    2026Hepatobiliary surgery and nutrition(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Paired-sample Analysis of ERG Expression and TMPRSS2-ERG Fusion in Treatment-induced Neuroendocrine Prostate Cancer.
    Ryuta Watanabe, Ryu Shigehisa, Tatsushi Kawada,Shinkuro Yamamoto,Satoshi Katayama,Atsushi Takamoto,Kenichi Nishimura,Noriyoshi Miura,Motoo Araki, Keiji Inoue,Takashi Saika, Chu-shikoku Japan Urological Consortium (CsJUC) Research Collaboration

    BACKGROUND/AIM:Prostate cancer is one of the most common malignancies in men. Although androgen deprivation therapy (ADT) offers substantial benefit, resistance to androgen signaling ultimately develops, leading to castration-resistant prostate cancer (CRPC). Approximately 10-17% of CRPC cases evolve into treatment-induced neuroendocrine prostate cancer (t-NEPC), an aggressive, androgen receptor (AR)-independent subtype. The TMPRSS2-ERG fusion gene is among the most frequent genomic alterations in prostate cancer; however, its involvement in t-NEPC development remains unclear. PATIENTS AND METHODS:We retrospectively analyzed nine Japanese cases of t-NEPC diagnosed across multiple institutions. Immunohistochemical staining for AR and ERG and RT-PCR for TMPRSS2-ERG fusion gene expression were performed on paired adenocarcinoma and t-NEPC samples. Clinical data - including prostate specific antigen levels, Gleason scores, metastatic patterns, and outcomes - were compared between ERG-positive and ERG-negative groups. RESULTS:ERG-positive prostate cancer was found in three of nine cases (33.3%), all of which were AR-positive, indicating that active AR signaling is required for TMPRSS2-ERG expression. ERG positivity was not clearly associated with prognosis or drug sensitivity, but time to NEPC differentiation tended to be shorter in ERG-positive cases. Only the e1e4 isoform of TMPRSS2-ERG was detected, while e2e4 was absent. CONCLUSION:This study highlights heterogeneity in TMPRSS2-ERG fusion dynamics during t-NEPC evolution and suggests a potential association between ERG expression and earlier NE differentiation. This study provides a rare opportunity to analyze paired pre- and post-NEPC tissues, offering valuable insight into the relationship between ERG and TMPRSS2-ERG fusion gene expression and clinical parameters.

    2026Anticancer research(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Predictive Nomogram for Recurrence after Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2)
    Ryuichi Yoshida,Kosei Takagi,Kazuya Yasui,Masayoshi Hioki,Takehiro Okabayashi,Toru Kojima,Yoshikatsu Endo,Daisuke Nobuoka,Kenta Sui,Masaru Inagaki, Susumu Shinoura,Masashi Kimura,

    Background/Objectives: Postoperative recurrence is a critical issue in the treatment of resectable pancreatic ductal adenocarcinoma (rPDAC). Moreover, the prognosis after early recurrence is extremely poor. This study aimed to develop a recurrence prediction model and to define early recurrence after upfront surgery (UFS) for rPDAC. Methods: This multicenter retrospective study included patients who underwent UFS for anatomically rPDAC between January 2013 and December 2017. Multivariate analyses were conducted to identify the risk factors for recurrence-free survival and to construct a recurrence prediction model. Subsequently, a minimum p value approach was used to determine the optimal cutoff values for early and late recurrence. Results: The cohort included 603 patients (325 men and 278 women). During the median follow-up period of 25 months (interquartile range, 15-38 months), 381 patients (63.2%) experienced a recurrence. Multivariate analyses revealed carbohydrate antigen 19-9 ≥37 U/mL (hazard ratio [HR], 1.58; p < 0.001), tumor size ≥ 2.2 cm (HR, 1.59; p < 0.001), lymph node metastasis (HR, 1.86; p < 0.001), R1 resection (HR, 1.56; p = 0.002), and no adjuvant chemotherapy (HR, 1.54; p < 0.001) as independent predictors. The recurrence prediction model demonstrated an area under the curve of 0.72-0.75. The optimal threshold for early and late recurrences was a recurrence-free interval of five months. Carbohydrate antigen 19-9 ≥ 156 U/mL was a significant predictor of early recurrence (OR, 3.28; p < 0.001). Conclusions: This study identified the prognostic risk factors for recurrence and developed a recurrence prediction model for patients undergoing UFS for rPDAC. Moreover, a recurrence-free interval of five months was identified as the optimal threshold for distinguishing between early and late recurrences.

    2026Cancers(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Dynamic Loss of Psoas Muscle Volume During Induction Chemotherapy Predicts Survival in Patients with Advanced Urothelial Carcinoma Receiving Avelumab Maintenance: A Multicenter Retrospective Study
    Ryutaro Shimizu,Shuichi Morizane,Noriya Yamaguchi,Satoshi Katayama,Tatsushi Kawada,Kensuke Bekku,Keita Kobayashi,Koji Shiraishi,Noriyoshi Miura,Ryuta Watanabe,Yoichiro Tohi,Hirohito Naito,

    BACKGROUND:Sarcopenia is increasingly recognized as a prognostic factor in oncology; however, most studies have focused on static baseline muscle mass in heterogeneous populations. Whether dynamic skeletal muscle loss during systemic therapy carries independent prognostic value, particularly in clinically stable patients with controlled disease, remains unclear. We investigated the prognostic relevance of three-dimensional volumetric muscle assessment in advanced urothelial carcinoma (UC) patients who achieved disease control with first-line platinum-based chemotherapy and subsequently received maintenance therapy. METHODS:This multicenter retrospective study included 82 patients with unresectable or metastatic UC across 10 institutions. Psoas muscle volume (PMV) was quantified using three-dimensional computed tomography (CT) reconstruction. The relative percentage change in PMV during induction chemotherapy (ΔPMV) was calculated as: (PMV at pre-maintenance - PMV at baseline)/PMV at baseline × 100. A predefined PMV loss ≥ 5% (defined as ΔPMV ≤ -5%) was considered clinically significant. Baseline cross-sectional muscle indices, including skeletal muscle index (SMI), total psoas index (TPI), and paraspinal muscle index (PMI), as well as inflammatory and nutritional markers, were evaluated. Overall survival (OS) was analyzed using multivariable Cox regression. RESULTS:During a median follow-up of 19 months, 35 deaths occurred. Baseline cross-sectional muscle indices (SMI, TPI, and PMI) were not associated with OS. In contrast, patients with PMV loss ≥ 5% (ΔPMV ≤ -5%) had significantly shorter OS. In multivariable analysis adjusting for clinical, inflammatory, and nutritional factors, PMV loss ≥ 5% remained independently associated with worse OS (HR 2.14, 95% CI 1.02-4.50, p = 0.044). Dynamic volumetric muscle decline may reflect clinically meaningful physiologic vulnerability despite tumor control. CONCLUSIONS:Dynamic loss of PMV during systemic therapy is a strong independent prognostic marker in advanced UC patients with controlled disease, whereas static baseline muscle indices lack prognostic significance. These findings highlight the clinical importance of preserving skeletal muscle mass during systemic therapy and support further investigation of targeted nutritional or supportive interventions.

    2026Nutrition and cancer(2026)
    引用
    AI阅读
    加入学术空间
    5Successful Treatment Using Pemigatinib in a Myeloid/lymphoid Neoplasm with Eosinophilia with FGFR1 Rearrangement and Rare Chromosomal Abnormalities.
    Masaya Abe, Fumiaki Konishi, Yuki Nakagawa,Kyotaro Ohno, Kumiko Yoshikawa, Nobuhiro Shimizu,Yasuharu Sato,Ichiro Takata,Toru Ueki, Hiroyuki Sugiura
    2026Leukemia & lymphoma(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 545 篇论文

    合作机构(100)

    岡山大学合作论文 167
    冈山大学医院合作论文 70
    岡山済生会総合病院合作论文 63
    Kagawa Prefectural Central Hospital合作论文 58
    倉敷中央病院合作论文 54
    Japanese Red Cross Narita Hospital合作论文 32
    东京大学合作论文 30
    藤田医科大学合作论文 30
    Mthatha General Hospital合作论文 29
    広島市立安佐市民病院合作论文 29

    机构统计